Want to see HK:1875 full AI Analyst Report?
Top Page
TOT BIOPHARM International Co. Ltd.
(1875)
Select Model
Select Model
Rating:49Neutral
Price Target:
HK$4.00
▲(60.00% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weakening fundamentals (2025 revenue drop, return to losses, and persistently negative free cash flow). Technicals are broadly neutral with mixed moving-average positioning and only modest momentum signals. Valuation is also constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Manageable Leverage
Manageable leverage and substantial equity relative to assets provide a reasonably stable financial base for continued drug development. This reduces balance-sheet pressure compared with highly indebted peers and preserves flexibility to fund operations or absorb periods of earnings volatility.
Negative Factors
Sharp Revenue Decline
The sharp 2025 revenue contraction indicates a material reversal in commercial momentum after several years of expansion. A sustained decline would reduce operating scale, weaken the funding base for oncology development, and make future revenue recovery more dependent on successful execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Manageable leverage and substantial equity relative to assets provide a reasonably stable financial base for continued drug development. This reduces balance-sheet pressure compared with highly indebted peers and preserves flexibility to fund operations or absorb periods of earnings volatility.
Read all positive factors
TOT BIOPHARM International Co. Ltd. (1875) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.91B
Dividend YieldN/A
Average Volume (3M)726.21K
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue Growth-51.10%
EPS Growth-2384.76%
CountryHK
Employees596
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.22
Shares Outstanding772,787,900
10 Day Avg. Volume601,520
30 Day Avg. Volume726,213
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.60
Price to Sales (P/S)2.18
P/FCF Ratio-60.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.18
Revenue Forecast (FY)HK$566.06M
TOT BIOPHARM International Co. Ltd. Business Overview & Revenue Model
Company Description
BioDlink International Co., Ltd. operates as a clinical-stage biopharmaceutical firm, dedicating its resources to the development and future commercialization of novel oncology drugs and therapeutic solutions. Its pipeline features several key pro...
How the Company Makes Money
TOT BIOPHARM makes money primarily through revenue generated from its biopharmaceutical business activities, which typically include: (1) product-based revenue from sales of approved drugs and other pharmaceutical products, where available; (2) mi...
TOT BIOPHARM International Co. Ltd. Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
62
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 501.12M | 747.64M | 1.10B | 780.63M | 442.18M | 76.33M |
| Gross Profit | 87.85M | 388.98M | 782.43M | 573.99M | 370.62M | 27.47M |
| EBITDA | -40.82M | -6.44M | 84.96M | 10.45M | -5.41M | -224.51M |
| Net Income | -162.14M | -100.37M | 34.76M | -37.76M | -49.92M | -261.22M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 1.26B | 1.51B | 1.43B | 1.26B | 710.26M |
| Cash, Cash Equivalents and Short-Term Investments | 263.69M | 328.47M | 381.26M | 351.60M | 517.63M | 155.38M |
| Total Debt | 350.93M | 383.72M | 395.47M | 345.65M | 289.53M | 208.56M |
| Total Liabilities | 558.84M | 633.75M | 779.12M | 739.41M | 546.59M | 375.17M |
| Stockholders Equity | 614.59M | 626.08M | 729.65M | 686.69M | 713.88M | 335.09M |
Cash Flow | ||||||
| Free Cash Flow | -40.69M | -26.93M | -7.17M | -146.77M | -180.19M | -290.45M |
| Operating Cash Flow | -18.69M | 16.14M | 116.40M | 56.43M | 59.93M | -175.14M |
| Investing Cash Flow | -16.56M | -43.07M | -122.50M | -164.10M | -282.76M | -108.39M |
| Financing Cash Flow | -20.60M | -25.66M | 34.18M | 38.23M | 481.24M | 212.08M |
TOT BIOPHARM International Co. Ltd. Technical Analysis
Neutral
2.50
Price Trends
3.64
Positive
3.88
Negative
3.69
Positive
Market Momentum
0.04
Positive
50.69
Neutral
19.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1875, the sentiment is Neutral. The current price of 2.5 is below the 20-day moving average (MA) of 3.89, below the 50-day MA of 3.64, and below the 200-day MA of 3.69, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 50.69 is Neutral, neither overbought nor oversold. The STOCH value of 19.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1875.
TOT BIOPHARM International Co. Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | HK$35.93B | 36.15 | 20.41% | ― | 32.63% | 8.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$7.58B | 26.26 | 17.36% | ― | 46.90% | ― | |
49 Neutral | HK$2.91B | -14.80 | -26.14% | ― | -51.10% | -2384.76% | |
46 Neutral | HK$8.10B | -42.05 | -10.27% | ― | -31.77% | -177.01% | |
46 Neutral | HK$34.13B | -75.42 | -7.32% | ― | 34.83% | 58.94% | |
44 Neutral | HK$7.96B | -71.58 | -9.49% | ― | 68.12% | 81.84% |
* Healthcare Sector Average
HK:1875
TOT BIOPHARM International Co. Ltd.
3.80
1.45
61.70%
HK:9966
Alphamab Oncology
8.45
-2.41
-22.19%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.64
-17.28
-49.48%
HK:2157
Lepu Biopharma Co. Ltd. Class H
4.15
-4.05
-49.39%
HK:2171
CARsgen Therapeutics Holdings Ltd.
13.43
-7.31
-35.25%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
67.20
-13.90
-17.14%
TOT BIOPHARM International Co. Ltd. Corporate Events
BioDlink’s CDMO Surge and WuXi XDC Deal Reshape Growth Strategy
Aug 21, 2026
BioDlink International Company Limited operates as a contract development and manufacturing organization in the biopharmaceutical sector, focusing on chemistry, manufacturing and controls projects and biologic drug production services. The company...
BioDlink updates corporate logo while keeping shareholder arrangements unchanged
Aug 11, 2026
BioDlink International Company Limited has introduced a new corporate logo effective 11 August 2026, which will gradually appear on its interim and annual reports, stock exchange announcements, circulars, notices, share certificates and press rele...
BioDlink Sets August Board Meeting to Approve Interim 2026 Results
Jul 10, 2026
BioDlink International Company Limited, a Hong Kong–incorporated company listed under stock code 1875, oversees its operations through a board led by chairperson and executive director Dr. Jincai Li, supported by a mix of non-executive and i...
BioDlink reshapes company secretarial team under HKEX waiver
Jun 26, 2026
BioDlink International Company Limited has reshuffled its corporate secretarial team, with joint company secretary Mr. Chen Yifan resigning effective 26 June 2026 and Ms. Fang Yuan stepping in as his replacement alongside existing joint company se...
BioDlink Wins Unanimous Shareholder Backing for Board Mandates at AGM
Jun 26, 2026
BioDlink International Company Limited reported that all resolutions at its 26 June 2026 annual general meeting were passed by poll with 100% approval from votes cast. Shareholders endorsed the 2025 audited financial statements, re‑elected a...
BioDlink Wins RMB19 Million Monoclonal Antibody Manufacturing Mandate from WuXi Biologics
Jun 16, 2026
BioDlink International has signed a process development and manufacturing services agreement with WuXi Biologics under which it will supply ten batches of monoclonal antibody intermediates by the end of 2026 for a total fee of RMB19 million. The d...
BioDlink Shareholders Approve CDMO Master Agreement With WuXi XDC
Jun 11, 2026
Shareholders of BioDlink International Company Limited have approved a CDMO master services agreement with WuXi XDC Cayman Inc. at an extraordinary general meeting held on 11 June 2026. The resolution, which also endorsed annual caps for the agree...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.